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Abstract: Cyclodextrins (CDs), a group of oligosaccharides formed by glucose units bound together
in a ring, show a promising ability to form complexes with drug molecules and improve their
physicochemical properties without molecular modifications. The stoichiometry of drug/CD
complexes is most frequently 1:1. However, natural CDs have a tendency to self-assemble and form
aggregates in aqueous media. CD aggregation can limit their solubility. Through derivative formation,
it is possible to enhance their solubility and complexation capacity, but this depends on the type of
substituent and degree of substitution. Formation of water-soluble drug/CD complexes can increase
drug permeation through biological membranes. To maximize drug permeation the amount of added
CD into pharmaceutical preparation has to be optimized. However, solubility of CDs, especially that
of natural CDs, is affected by the complex formation. The presence of pharmaceutical excipients,
such as water-soluble polymers, preservatives, and surfactants, can influence the solubilizing abilities
of CDs, but this depends on the excipients’ physicochemical properties. The competitive CD
complexation of drugs and excipients has to be considered during formulation studies.
Keywords: cyclodextrin; complex; solubility; poorly soluble drug
1. Introduction
Cyclodextrins (CDs) are cyclic oligosaccharides, formed by α-1,4-linked glucose units,
with a hydrophilic outer surface and a lipophilic central cavity [1–4]. α-Cyclodextrin (αCD),
β-cyclodextrin (βCD), and γ-cyclodextrin (γCD) are natural products that can be found in small
amounts in various fermented consumer products, such as beer. Although the unsubstituted natural
αCD, βCD, and γCD, and their complexes, are hydrophilic their solubility in aqueous solutions is
somewhat limited, especially that of βCD. Consequently the more soluble βCD derivatives, such as
2-hydroxypropyl-βCD (HPβCD) and sulfobutylether βCD sodium salt (SBEβCD), are preferred for
use in aqueous pharmaceutical solutions, such as parenteral drug formulations, even though both αCD
and γCD can be found at low concentrations in parenteral formulations [5]. Monographs for αCD,
βCD, and γCD and two βCD derivatives are in the European Pharmacopoeia and the United States
Pharmacopeia/National Formulary (Table 1). CDs are included in over 40 marketed pharmaceutical
products worldwide, in addition to numerous food, cosmetic, and toiletry products [2,6,7].
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Table 1. Cyclodextrins with pharmacopoeia monographs.
Cyclodextrin n R = H or Abbreviation Synonyms PharmacopoeiaMonographs 1
α-Cyclodextrin 0 αCD alfadex Ph.Eur., USP-NF, JPC
β-Cyclodextrin 1 βCD betadex Ph.Eur., USP-NF, JPC
2-Hydroxypropyl-β-cyclodextrin 1 -CH2CHOHCH3 HPβCD hydroxypropylbetadex Ph.Eur., USP-NF
Sulfobutylether
β-cyclodextrin sodium 1 -(CH2)4SO3
− Na+ SBEβCD betadex sulfobutylether sodium USP-NF
γ-Cyclodextrin 2 γCD gammadex Ph.Eur., USP-NF, JPC
1 The European Pharmacopoeia (Ph.Eur.), the United States Pharmacopeia and the National Formulary (USP-NF),
and the Japanese Pharmaceutical Codex (JPC).
Due to their ability to change physiochemical properties of drugs and other compounds, CDs are
frequently referred to as enabling pharmaceutical excipients. CDs enable delivery of poorly water-soluble
and chemically-unstable drugs to the body. Hence, CDs are able to convert biologically-active compounds
that lack drug-like physiochemical properties into therapeutically-effective drugs. CDs (referred to
as host molecules) are able to form inclusion complexes with drugs (referred to as guest molecules)
by taking part of a drug molecule into the central CD cavity. This will change the physiochemical
properties of the included drug. Formation of a drug/CD inclusion complex can, for example, increase
the aqueous solubility of the drug, increase its chemical and physical stability, and enhance drug delivery
through biological membranes. No covalent bonds are formed or broken during the complex formation
and, in aqueous solutions, drug molecules bound within the CD inclusion complex are in dynamic
equilibrium with free drug molecules (Figure 1) [8]. Drug molecules are readily released from the
complex upon media dilution or by competitive complexation [9,10]. One or more drug molecules
can form a complex with one CD molecule and one or more CD molecules can form a complex
with one drug molecule. However, most commonly, one drug molecule (D) forms a complex with
one CD molecule. The stoichiometry of the drug/CD complex (D/CD) is then 1:1 and the equilibrium
constant (K1:1) defined as [11,12]:
D + CD
K1:1
D/CD (1)
The value of K1:1 can be calculated by Equation (2) where S0 is the intrinsic solubility of the drug
(i.e., the solubility in the aqueous media when no CD is present), and Slope is the slope of the linear
(i.e., AL-type) drug-CD phase solubility diagram (Figure 2):
K1:1 =
Slope
S0 ·(1 − Slope) (2)
However, the value of K1:1 is highly sensitive towards small changes in S0 and for poorly-soluble
drugs it can be complicated to obtain accurate S0 values. Furthermore, self-association of lipophilic drug
molecules in aqueous media can lead to erroneous results. Under such conditions, it can be more accurate
to determine the complexation efficacy (CE):
CE = K1:1 · S0 = Slope(1 − Slope) (3)
Drug/CD complexes, especially those of the natural CDs, have tendency to self-assemble in aqueous
solutions to form aggregates (Figure 1). At elevated CD concentrations these aggregates can become
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large and precipitate as solid microparticles [1]. In addition, the natural CDs and their complexes have
limited solubility in aqueous solutions. These solubility limitations can give rise to characteristic B-type
phase-solubility diagrams displayed in Figure 2 [11].
Figure 1. Formation of a cyclodextrin inclusion complex in an aqueous solution and self-assembly of
cyclodextrin complexes.
Figure 2. Types of phase-solubility diagrams according to Higuchi and Connors [11] showing how the
total drug solubility changes with increasing CD concentration. A-type diagrams are formed when
the drug/CD complex is soluble in the aqueous complexation media and they are usually associated
with the water-soluble CD derivatives. B-type diagrams are observed when the complex has limited
solubility in the media and these are usually associated with the natural CDs that have limited solubility
in aqueous media. AL: linear diagram; AP: positive deviation from linearity; AN: negative deviation
from linearity; BS: the complex has some but limited solubility; BI: the complex is insoluble.
The biopharmaceutical classification system (BCS) divides orally-administered drugs into four cases
based on their solubility and intestinal permeability [13]. Drugs possessing favorable physiochemical
properties are in Class I. They have adequate aqueous solubility and permeability to be well-absorbed
from the gastrointestinal tract. In general, they gave good oral bioavailability. Drugs in Class II have
inadequate aqueous solubility, but good permeability when in solution. Thus, their absorption from
the gastrointestinal tract is slow and dissolution dependent. Drugs in Class III have adequate aqueous
solubility but poor permeability, most often due to their very hydrophilic nature. Frequently such drugs
are administered via parenteral injection. Finally, drugs in Class IV have both low aqueous solubility
and are poorly absorbed from the gastrointestinal tract. Thus, they have very poor oral bioavailability
and can be difficult to formulate as parenteral solutions. CDs can improve oral bioavailability of Class II
drugs and sometimes also of Class IV drugs while they have negligible effect on Class III drugs and can
under certain conditions even hamper absorption of some Class I drugs [10]. The BCS can be adapted to
other types of dosage forms intended for non-oral administration [14]. Here the aqueous solubility of CDs
and their complexes is reviewed, as well as the effect of CD concentrations on drug permeation through
biological membranes.
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2. Physiochemical Properties of Cyclodextrins
The secondary hydroxyl groups on the CD molecule are located on the wider rim of the molecule and
the primary hydroxyl groups on the narrow rim make them hydrophilic [12,15]. Due to their hydrophilic
outer surface and their large number of hydrogen bond donors and acceptors, CDs have very negative
LogPo/w value (i.e., the logarithmic value of the octanol/water partition coefficient) (Table 2) [4,16].
In aqueous solutions, CDs are susceptible to acid hydrolysis at low pH resulting in ring opening and
formation of various linear oligosaccharides and glucose units, but they are stable under alkaline conditions.
The hydroxyl groups attached to the rim start to deprotonate at pH about 12 [17,18]. Depending on the
determination method and the location of the hydroxyl groups, the pKa values of the natural CDs have
been reported to be between 12.1 and 13.5 [19]. The main difference of the three natural CDs, besides the
size of their central cavity, is their aqueous solubility (Table 2). βCD is the least soluble but, at the same
time, possesses the most suitable cavity size for complex formation with many drugs [20,21]. The poor
solubility can be explained in term of molecular rigidity of CD molecule, and the effect caused by the
intermolecular hydrogen bonding in the crystal state [22,23]. Particularly, the hydrogen bond formation
between neighboring C2-OH and C3-OH in the βCD molecule leads to the so-called complete secondary
belt resulting in inflexible structure and reduced ability of the βCD molecule to form intermolecular
hydrogen bond with surrounding water molecules [15]. Molecular dynamic simulations have shown high
water density and strong ordering of water molecules around the βCD molecule [24,25]. This indicates
that water molecules surrounding dissolved βCD molecules have unfavorable enthalpy and low entropy,
which can explain the low water solubility of βCD compared to other natural CDs. In contrast, αCD has
incomplete belt of hydrogen bonds and γCD has non-coplanar structure. Consequently, both αCD and
γCD possess higher solubility in water.
To enhance solubilizing potential of the natural CDs, including their complexation capacity,
CD derivatives have been prepared by reacting the secondary and/or primary OH groups of the
molecule with a wide variety of substituents [26,27]. Randomly methylated and hydroxypropylated
CDs and sulfobutylether CDs are manufactured on an industrial scale and often used in pharmaceutical
products, whereas other CD derivatives are utilized for specific purposes, such as the removal of
pollutants from the environment and reagents for drug analysis [28,29]. Attachment of these substituents
disrupts the regular hydrogen bonding network within native CD molecule increasing their ability to
interact with the surrounding water molecules [30]. The result can be over 100-fold increase in their
aqueous solubility [31–34]. For example, the sulfobutylether βCD anionic alkyl chains form an extremely
hydrophilic exterior surface. These anionic chains provide for electrostatic repulsion resulting in extension
of the hydrophobic central cavity and thereby intensifying its solubilizing potential [35]. Most frequently,
modified natural CDs exist in amorphous isomeric mixtures of various degree of substitution (DS). The DS
has a great influence on the physicochemical properties of CDs and their ability to form complexes.
For instance, randomly-methylated βCD (RMβCD) has the highest solubility in water when the degree
of substitution is about 14, that is, when two-thirds of the OH-groups have been replaced by methoxy
groups [36]. Increasing the DS above 14 decreases the RMβCD solubility. The cavity diameter of CD
derivatives is similar to their parent CDs. However, an effect of substituent location on the cavity volume
has been observed [37]. It has been observed that the hydroxypropylation of OH groups at the O-2 position
results in a more spread out configuration, whereas the substitution of OH groups at the O-6 position
reduces the water density inside the CD cavity [30,38,39]. Unlike native CDs that have negligible surface
activity, some CD derivatives manifest such behavior. It is reported that methylated and hydroxyalkylated
CD molecules reduce the surface tension of water [40,41]. The increase in surface activity is proportional
to the increased degree of substitution. On the other hand, derivatives with polar ionic groups, such as
carboxylate ion and sulfobutyl groups, have no influence on surface activity [35]. Table 2 lists dimensional
structures and physicochemical properties of the three most common natural CDs and some of their more
common derivatives.
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Table 2. The cavity size and some important physicochemical properties of natural CDs and some of their derivatives.
Types Substituent 1 DS
Inner Cavity
Diameter (Å)
Hydrogen
Donors
Hydrogen
Acceptors
Solubility
(mg/mL, 25 ◦C)
Log
Po/w
Surface Tension
(mN/m) References
Naural CD
αCD H 0 4.7–5.3 18 30 145 −13 71 [1,42]
βCD H 0 6.0–6.5 21 35 18.5 −14 71 [1]
γCD H 0 7.5–8.3 24 40 232 −17 71 [1]
Modified CD
HPαCD -CH2-CHOH-CH3 3.6 4.5–5.3 18 36 - - - [43]
CMβCD -CH2-CO2H 3–5 - 21 49 50 −4.9 - [32]
DMβCD -CH3 12–16 5.8–6.5 7 35 570 - 62 [34]
RMβCD -CH3 9.7–13.6 - 9 35 >500 −6 57.5–54.1 [1,44,45]
TMβCD -CH3 21 4–7 0 35 310 - 56 [34,46]
HEβCD -CH2-CH2OH 3.6 - 21 42 >2000 - - [26,47]
HPβCD -CH2-CHOH-CH3 2.8–10.5 6.0 25 39 >1200 −11 54.8–57.5 [1,47]
SBEβCD (CH2)4-SO3Na 6.2–6.9 - 21 35 >1200 <−10 71 [1]
HPγCD -CH2-CHOH-CH3 3.0–5.4 8.0 24 45 800 −13 - [1]
SBEγCD (CH2)4-SO3Na 4–8 - - - - - - [43,48]
SUG -SCH2CH2CO2Na 8 7.5–8.3 24 48 Very soluble −16 72.2 [1]
Branched CD
G1βCD glucosyl 1 6.0–6.5 24 40 970 −9 71 [26,49]
G2βCD maltosyl 1 - 27 45 >1500 −9 72 [33]
GUGβCD glucoronylglucosyl 1 - - - >2000 - 73 [33]
1 DS is defined as the average number of substituents per one CD molecule; DMαCD, dimethyl-αCD; TMαCD, trimethyl-αCD; HPαCD, 2-hydroxypropyl-αCD;
CMβCD, carboxymethyl-βCD; DMβCD, dimethyl-βCD; TMβCD, trimethyl-βCD; HEβCD, hydroxyethyl-βCD; DMγCD, dimethyl-γCD; TMγCD, trimethyl-γCD;
HPγCD, hydroxypropyl-γCD, SBEγCD, sulfobutylether-γCD sodium salt; SUG, sugammadex; G1βCD, glucosyl-βCD; G2βCD, maltosyl-βCD; GUGβCD, glucoronyl-glucosyl-βCD.
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3. How Much Solubilization Is Needed?
CDs can both enhance and hamper drug permeation through biological membranes. Although active
drug transport through biological membranes does exist, drug molecules are mainly transported via passive
diffusion through the membranes. In general, the driving force for passive diffusion through an aqueous
environment (e.g., mucus) into and through membranes, such as mucosa is not the concentration
gradient but the gradient of chemical potential, which is a continuous function across interfaces [50].
Likewise, the partitioning of drug molecules from a membrane exterior into the outermost membrane layer
is controlled by the chemical potential. Thus, maximum drug permeation from an aqueous exterior into
and through biological membrane is expected to be obtained when the drug is at its highest thermodynamic
potential [50]. In other words, maximum drug permeation is obtained when the aqueous membrane
exterior is saturated with the drug [51]. However, the amount of drug permeating through a membrane
also depends on the concentration of dissolved drug at the membrane exterior. Figure 3 shows the flux
of hydrocortisone through hairless mouse skin in vitro. The skin was mounted in a Franz diffusion cell
where the donor phase was unstirred (i.e., consisted of an unstirred diffusion layer), but the receptor phase
was stirred. The total amount of hydrocortisone (i.e., dissolved and undissolved) in the donor phase was
kept constant at 16 mg/mL while the CD concentration was increased from 0 to 20% (w/v). About 8% (w/v)
CD was needed to solubilize 16 mg of hydrocortisone in 1 mL of the donor phase (i.e., the aqueous medium).
Thus, increasing the CD concentration from 0 to 8% (w/v) increases the amount of dissolved drug in
the donor phase. At these CD concentrations, the donor phase was always saturated with the drug and,
thus, the drug is always at its maximum thermodynamic potential. Under these conditions, the drug
molecules have maximum tendency to leave the donor phase and partition into the skin. However, only
dissolved drug molecules can partition into the skin and, thus, increasing the concentration of dissolved
drug molecules through formation of water-soluble drug/CD complexes increases the number of drug
molecules that are able to partition into the skin and then permeate through the skin into the receptor phase.
Increasing the CD concentration beyond 8% (w/v) decreases the thermodynamic potential of the drug.
The solubility of hydrocortisone in 10% (w/v) CD solution is about 20 mg/mL and about 26 mg/mL at
13% (w/v) CD. The donor phase was no longer saturated with the drug and the drug molecules have
decreased tendency to leave the donor phase and partition into the membrane. To ensure maximum drug
permeation through biological membranes one should only add just enough CD to the pharmaceutical
formulation to solubilize the entire drug dose. Too little or too much CD will result in less than optimum
drug flux through the membrane. However, small excess CD has to be included in aqueous drug solutions
to prevent drug precipitation during storage and handling.
Figure 3. The effect of maltosyl-β-cyclodextrin concentration on the permeation of hydrocortisone
through hairless mouse skin in vitro. The amount of hydrocortisone in the aqueous donor medium
was kept constant 16 mg/mL but the maltosyl-β-cyclodextrin concentration was from 0 to 20%
(w/v). Below 8% (w/v) maltosyl-β-cyclodextrin the medium was hydrocortisone suspension in water,
but hydrocortisone solution in water at higher concentrations. Based on unpublished results.
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In solid dosage forms such as tablets adequate amount of CD should be included to prevent
dissolution controlled drug absorption from the gastrointestinal tract [10]. Excess CD can hamper
absorption from the gastrointestinal tract and, for example, αCD is used to bind and prevent absorption
of dietary fat [52]. The unsubstituted naturalαCD,βCD, and γCD frequently form drug/CD complexes
that have limited solubility in water. However, their solubility is most often sufficient to prevent
dissolution limited absorption, and since natural CDs have lower molecular weight than their more
water-soluble derivatives their formulation bulk will be lower. General observations regarding the
amount of CD to be included in pharmaceutical formulations are listed in Table 3.
Table 3. In general, pharmaceutical formulations should contain sufficient CD to solubilize the entire
drug dose. However, how much solubilization is needed will depend on the formulation.
Formulation Amount of CD Comments
Parenteral solutions
Sufficient to solubilize the
drug dose in, for example,
10 mL of water.
Significant excess CD (as much as two to three times
what is needed to solubilize the drug) is frequently
included in parenteral formulations, especially those that
are given intravenously. This will not affect the drug
pharmacokinetics since the drug is almost
instantaneously released from the complex
upon dilution in the blood circulation.
Solid oral dosage forms
(e.g., tablets and capsules)
Sufficient to increase
aqueous solubility the drug
dose to prevent dissolution
controlled absorption.
The formulation bulk usually limits the amount of CD
that can be included in solid dosage forms. For example,
if βCD (molecular weight 1135 Da) is used in a solid
dosage form containing 100 mg of a drug with molecular
weight 250 Da the formulation bulk will be increased by
over five-fold.
Oral solutions
Sufficient to dissolve the
drug dose in the
aqueous vehicle.
Excess of CD (e.g., ≥20) should be used to prevent drug
precipitation upon storage and usage of the formulation.
Due to formulation dilution in the gastrointestinal tract
some excess CD will not hamper the drug release.
However, large excess (over 50 to 100) can hamper the
drug release.
Topical solutions with limited
dilution upon administration
(e.g., eye drops)
Sufficient to dissolve the
drug dose in the
aqueous vehicle.
Only a small excess of CD (e.g., 10 to 20%) should be
used to prevent drug precipitation upon storage and
usage of the formulation. Excess amounts of CD (e.g.,
more than 10%) can reduce topical bioavailability of
the drug.
4. The Effect of the Guest Molecule on the Cyclodextrin Solubility
Not only are aqueous solubilities of drugs affected by the formation of drug/CD complexes,
but also that of the CDs themselves. According to the phase-solubility diagram classification system
that was introduced by Higuchi and Connors [11], linear AL-type diagrams show that the total
drug solubility increases as a function of CD concentration through formation of soluble drug/CD
complexes. If one molecule of drug forms a complex with one molecule of CD, the slope of a straight
line is less than unity and the value of K1:1 can be calculated by applying Equation (2). AP- or AN-type
phase-solubility diagrams (i.e., displaying positive or negative deviation from linearity, respectively)
suggest formations of higher-order drug/CD complexes [20,53]. If the slope of a linear diagram is
greater than unity, but less than 2, the complex formed is likely to be of second, or higher, order with
respect to the drug, but first-order with respect to CD. For example, a K2:1 value of drug/CD complex
can be determined by [46]:
K2:1 =
slope
(2− slope)S20
(4)
The AP-type phase-solubility diagram suggests the formation of higher-order complexes with respect
to CD (e.g., formation of 1:2 drug/CD complex). The complex stoichiometry and equilibrium constant
(K2:1) can then be determined by fitting the solubility results to a quadratic model [20,54]. The tendency
of a given drug and CD to form a complex is expressed by a stability constant for the complex (Km:n),
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where m and n are the number of molecules of the drug and CD forming the complex, respectively, or
the equilibrium binding constant (Ka) defined by the ratio of association (ka) and dissociation (kd) rate
constants [55,56]. The Ka values of most drug/CD complexes are less than 105 M−1, indicating that the
drug and CD interactions are relatively weak [20,56]. Moreover the forward (ka) and reverse (kd) reactions
are very fast and the relaxation time is short (less than 1 s) [55,57], indicating that drug and CD molecules in
complex are in rapid equilibrium with free molecules in the solution. Thus, in aqueous solutions drug/CD
complexes are in dynamic equilibrium with free drug and CD molecules. Studies of dissolved γCD in
aqueous complexation media of indomethacin/γCD, diclofenac sodium/γCD, and amphotericin B/γCD
(all of which display AL-type phase-solubility diagrams) show that the determined concentrations of γCD
are almost identical to the initial concentration of dissolved γCD before the addition of the drug [58].
The influence of drug concentration on CD solubility in complexation media is negligible when the
phase-solubility diagram of the drug/CD complex presents as A-type (Figure 4a).
In general, the water-soluble CD derivatives form A-type phase-solubility diagrams, whereas the
B-type diagrams are mainly observed when the natural CDs form complexes with poorly-soluble drugs [20].
The B-type phase-solubility diagrams indicate the formation of complexes with limited solubility in the
complexation media. The initial linear region of Bs-type diagrams can be regarded as AL-type diagrams.
In this region of the diagrams drug molecules do not affect the CD solubility. In the plateau region of the
B-type diagram the drug solubility is constant even when the CD concentration is increased, indicating
the formation of drug/CD complexes with limited solubility and that the CD solubility is depressed by
the presence of the drug [58,59]. The amount of dissolved CD and drug in aqueous complexation media
are constant through the length of plateau region (Figure 4b) [59,60]. However, the amounts of drug and
CD in the precipitate can differ. Schönbeck reports that precipitate obtained from phase-solubility studies
consists of solid drug (i.e., hydrocortisone in excess) and precipitated drug/γCD complex. The ratio of
γCD to drug in precipitate increases as a function of the γCD concentration (i.e., the amount of precipitated
drug decreases, whereas the amount of precipitated drug/γCD complex increases) indicating that the
stoichiometry of the drug/CD inclusion complex gradually changes from 1:1 to higher-order drug/CD
complexes [61]. Since the solubility of the drug/CD complex is limited, higher-order drug/CD complexes
precipitate resulting in decreased CD solubility in the aqueous complexation media. The descendent region
of B-type phase-solubility diagrams show that solubility of the drug decreases when the concentration
of CD increases, indicating that CD preferably forms self-assembled aggregates and the solubility of
CD gradually increases even in the presence of the drug [60]. The absence of solid pure drug in the
precipitate from phase-solubility studies also indicates that only higher-order drug/CD complexes are
being formed [61]. In conclusion, the CD solubility, especially that of the natural CDs, can be decreased
in the presence of drugs if high-order drug/CD complexes, for example 1:2 or 2:1, are formed and then
precipitated from the media.
Figure 4. Cont.
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Figure 4. The phase-solubility diagram of hydrocortisone/HPγCD (a) [58] and hydrocortisone/γCD
(b) [59] complex. Concentrations of the soluble drug (open circle) and CD (filled circle) are plotted
against the concentration of total CD.
5. Excipients and Cyclodextrin Solubility
In pharmaceutical products, not only drugs and CDs are present as drug/CD complexes,
but also various excipients, such as antioxidants, antimicrobial agents, surfactants and polymers.
These excipients can enhance or hamper the CD solubilization of drugs, as shown in Table 4.
Preservatives, such as propyl- and methylparaben, can compete with drug molecules and expel
them from the CD cavities and, thus, reduce CD solubilization of the drugs [62,63]. In addition,
CD complexation of the preservatives can reduce their antimicrobial efficacy. Therefore, formulation
scientists need to adjust the amount of preservative in CD-containing formulations to obtain the
desired preservative efficacy and safety [64]. The additive or synergistic effects of excipients on the
drug solubility through CD inclusion complexes have been reviewed [20,65]. Various additives that
are commonly used in pharmaceutical formulations, such as organic acids or bases, organic salts
(counterions), cosolvents, metal ions, and water-soluble polymers, can increase the complexation
efficacy (CE) of CDs via stabilization and solubilization of drug/CD nanoparticles. Recently, we have
shown that CDs and drug/CD complexes can self-assemble and form complex aggregates in aqueous
solutions, which can enhance the drug solubility [54,66,67]. Water-soluble polymers play an important
role in the stabilization of aggregates. Formation of ternary drug:CD:polymer complexes can be
promoted by heating the media, for example, in an autoclave (121 ◦C for 15–20 min) or in an ultrasonic
bath (e.g., 60–70 ◦C for 1 h) [68]. It has been shown that the addition of small amounts of water-soluble
polymer reduces the formulation bulk, decreasing the manufacturing cost and increasing the possibility
of using CDs as solubilizers in various solid dosage forms. For instance, the amount of βCD or SBEβCD
required to solubilize 3.0 mg of glibenclamide were 300 mg and 1200 mg, respectively. Addition of
hydroxypropyl methylcellulose (HPMC) to the binary complexes reduced the amount of CD in the
formulation to 120 mg and 250 mg, respectively [69].
The excipients in the pharmaceutical formulations containing CD may increase or decrease
the ability of CD to solubilize drugs depending on their nature and physicochemical properties.
Thus, the exact amount of CD needed in a given formulation should be determined by studies
(e.g., phase-solubility studies) in a medium which composition is close to that of the final formulation.
The competitive complexation effect of the secondary drug should also be considered [70].
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Table 4. Effects of some pharmaceutical excipients on the cyclodextrin solubilization.
Excipients Examples Effect on Complexation Enhancement Some Brief Observations References
Acids, bases,
inorganic/organic salts
hydrochloride, citrate,
aspartate, mesylate, maleate,
tartrate, phosphate, acetate
Increase intrinsic solubility of drugs (S0)
and/or the apparent stability constant (K1:1)
resulting in increased CE
Salt formation of ziprasidone mesylate enhance the CE of drug up to 100
and 240 times in aqueous HPβCD and SBEβCD solutions when compared
with the free base of drug
[71]
Ternary complex of terfenadine/βCD/inorganic acid (phosphate, citrate)
induce the synergistic effect of CD solubilization [72]
The addition of sodium acetate into the complexing medium containing βCD
could increase hydrocortisone solubility up to 220% [73]
Enhance S0 but in most cases decrease K1:1
K1:1 of fluasterone/HPβCD complex decreases with increasing ethanol
concentration but the drug solubility increased at high ethanol
concentration (>40% v/v)
[74]
Cosolvents ethanol, propylene glycol (PG) Ternary complex of diazepam/PG/βCD increased the diazepam solubility
than that of the mixture of PG and water [75]
Hamper complexation by the
competitive effect
At higher concentrations of PG, the methyltestosterone solubility in
presence of HPβCD decreased possibly due to the complex dissociation [76]
Water-soluble polymers HPMC, Na CMC, PVA, PVP Formation of ternary complex(drug/CD/polymer) that can increase K1:1
Polymers and CDs can form water-soluble complexes with poorly
water-soluble drugs, for example, acetazolamide, carbamazepine
hydrocortisone, naproxen, pregnenolone, tropicamide, etc. have been reviewed
Synergistic solubilization effect is possible through micellar-like solubilization
or stabilization of self-assembled CD and/or CD complex aggregates
[20,77–79]
Metal ions Mg2+
Enhance CE by increasing S0 via formation
of drug/CD/metal ion complexes
Synergistic solubilization of quinolone was obtained when the addition of Mg2+
to the drug/HPβCD complexes
[80]
Hydroxypropyl methylcellulose (HPMC); sodium carboxymethylcellulose (Na CMC); polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP).
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6. Conclusions and Directions
Various physiochemical properties of drugs can be altered through CD complexation, especially
drug solubility in aqueous biological media. In aqueous media, drug molecules of appropriate size
and structure will enter into the central cavity of CD molecules to form water-soluble complexes
and, frequently, enhanced total drug solubility is observed. AL-type phase solubility diagrams
represent linear relationships between concentrations of dissolved drug and amounts of CD added
to an aqueous medium. However, when B-type diagrams are observed, the CD molecules and their
complexes self-assemble to form aggregates that possess limited solubility. While drug/CD complexes
are in dynamic equilibrium with free drug and CD molecules in aqueous media, CD aggregates
frequently precipitate from the media. The solid CD aggregates decrease CD solubility and this
will, again, influence formation of drug/CD complexes. Pharmaceutical excipients, for example
water-soluble polymers, are able to hamper this type of CD precipitation via formation of ternary
complexes leading to enhanced CD complexation efficacy. Since CD forms complexes with wide
variety of guest molecules, including drugs and pharmaceutical excipients, competitive complexation
should always be take into account. Therefore, the amount of CD and the type and composition of
pharmaceutical excipients used in pharmaceutical formulation needs to be carefully selected.
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Abbreviations
The following abbreviations are used in this manuscript:
CD Cyclodextrin
CE Complexation efficiency
CMβCD Carboxymethyl-βCD
DMβCD Dimethyl-βCD
DMαCD Dimethyl-αCD
DMγCD Dimethyl-γCD
DS Degree of substitution
G1βCD Glucosyl-βCD
G2βCD Maltosyl-βCD
GUGβCD Glucoronyl-glucosyl-βCD
HEβCD Hydroxyethyl-βCD
HPMC Hydroxypropyl methylcellulose
HPαCD 2-hydroxypropyl-αCD
HPγCD Hydroxypropyl-γCD
Na CMC Sodium carboxymethylcellulose
PVA Polyvinyl alcohol
PVP Polyvinyl pyrrolidone
SBEγCD Sulfobutylether-γCD
SUG Sugammadex
TMβCD Trimethyl-βCD
TMαCD Trimethyl-αCD
TMγCD Trimethyl-γCD
αCD α-Cyclodextrin
βCD β-Cyclodextrin
γCD γ-Cyclodextrin
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